Pharma Mar (LTS:0RC6) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RC6 Pharma Mar SA LTS:0RC6
70 GF Score
Price €73.28
GF Value €80.18
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Pharma Mar Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharma Mar  (LTS:0RC6) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pharma Mar Cyclically Adjusted PB Ratio Related Terms


Pharma Mar Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Cyclically Adjusted PB Ratio Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.32 13.86 7.45 12.19 9.75

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.95 13.66 9.75 11.81 9.83

LTS:0RC6 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted PB Ratio falls into.


LTS:0RC6
70GF Score
Pharma Mar SA LTS:0RC6
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pharma Mar's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Pharma Mar's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.466/131.3300*131.3300
=14.466

Current CPI (Jun. 2026) = 131.3300.

Pharma Mar Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.167 100.333 4.145
201609 3.030 99.737 3.990
201612 2.633 101.842 3.395
201703 2.489 100.896 3.240
201706 2.328 101.848 3.002
201709 1.899 101.524 2.457
201712 1.246 102.975 1.589
201803 1.174 102.122 1.510
201806 1.417 104.165 1.787
201809 1.531 103.818 1.937
201812 0.948 104.193 1.195
201903 0.407 103.488 0.516
201906 -0.205 104.612 -0.257
201909 -0.500 103.905 -0.632
201912 0.403 105.015 0.504
202003 4.184 103.469 5.311
202006 5.596 104.254 7.049
202009 5.306 103.521 6.731
202012 5.671 104.456 7.130
202103 7.041 104.857 8.819
202106 7.447 107.102 9.132
202109 7.909 107.669 9.647
202112 9.879 111.298 11.657
202203 11.145 115.153 12.711
202206 11.438 118.044 12.725
202212 12.313 117.650 13.745
202303 11.980 118.948 13.227
202306 11.698 120.278 12.773
202309 11.470 121.343 12.414
202312 10.966 121.300 11.873
202403 10.923 122.762 11.685
202406 10.282 124.409 10.854
202409 10.327 123.121 11.016
202412 11.855 124.753 12.480
202503 11.236 125.531 11.755
202506 11.467 127.251 11.835
202509 11.330 126.840 11.731
202512 14.506 128.400 14.837
202603 14.382 129.860 14.545
202606 14.466 131.330 14.466

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Pharma Mar (LTS:0RC6) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of €73.28 is trading 8.6% below its estimated GF Value™ of €80.18. GuruFocus considers Pharma Mar to be Fairly Valued.

Key valuation signals for LTS:0RC6:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €80.18 vs. price of €73.28 (8.6% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RC6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
70GF Score

Get the complete analysis for LTS:0RC6

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.28
Price
€80.18
GF Value